Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
TOT BIOPHARM International Co. Ltd. ( (HK:1875) ) has shared an announcement.
BioDlink International Company Limited has granted 13,350,000 restricted share awards, equivalent to about 1.73% of its issued share capital, to eight non-director employees under its 2024 Restricted Share Award Scheme. The awards, priced at HK$0.6 per share compared with a market price of HK$2.03 at the grant date, will vest in four equal tranches subject to performance targets tied to CDMO revenue and group EBITDA for 2026–2027 and multi‑year service conditions, reflecting management’s use of equity incentives to align key staff with the company’s medium‑term growth and profitability objectives, particularly in its CDMO business, although the scheme does not include a broader clawback mechanism beyond forfeiture on dismissal or misconduct.
The most recent analyst rating on (HK:1875) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on TOT BIOPHARM International Co. Ltd. stock, see the HK:1875 Stock Forecast page.
More about TOT BIOPHARM International Co. Ltd.
BioDlink International Company Limited is a Hong Kong–incorporated company listed on the Stock Exchange of Hong Kong (stock code: 1875). The group operates in the biopharmaceutical sector with a focus on contract development and manufacturing organization (CDMO) services and related biologics operations, targeting revenue and EBITDA growth from its CDMO business as a key strategic driver.
Average Trading Volume: 146,725
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.57B
Find detailed analytics on 1875 stock on TipRanks’ Stock Analysis page.